Skip to main content

Market Overview

Better Therapeutics To Go Public Via Mountain Crest SPAC Deal

Share:
Better Therapeutics To Go Public Via Mountain Crest SPAC Deal
  • Better Therapeutics Inc, a company developing prescription-only smartphone-based treatments for Type 2 diabetes and high blood pressure, has agreed to go public through a merger with a blank-check company Mountain Crest Acquisition Corp II (NASDAQ: MCAD)
  • The transaction is expected to close during this summer, and the combined entity will operate under the Better Therapeutics moniker and trade on the NASDAQ under the symbol 'BTTX.'
  • The deal values Better Therapeutics at $187 million, including debt.
  • The merger is expected to deliver up to $113 million in proceeds, including private investment rounds collecting $56 million from Farallon Capital, RS Investments, Sectoral Asset Management, Monashee Investment, and other undisclosed investors.
  • Better Therapeutics, founded in 2015, develops software for apps that treat patients, calling it prescription digital therapeutics. Its apps can be prescribed to help treat diabetes, heart disease, and other conditions using cognitive behavioral therapy.
  • The company's first prescription digital therapeutics (BT-001) is under evaluation in a pivotal trial to treat type 2 diabetes used under physician supervision.
  • The SPAC has raised $57.5 million in its initial public offering in January.
  • Price Action: MCAD shares are down 0.25% at $9.92 on the last check Wednesday.
 

Related Articles (MCAD + MCADR)

View Comments and Join the Discussion!

Posted-In: Briefs SPACs AttackBiotech News Health Care Offerings IPOs General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com